Fulton Breakefield Broenniman’s Gilead Sciences GILD Stock Holding History

Fulton Breakefield Broenniman’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-87,024	Closed	-$5.66M	–	105
2019 Q1	$5.66M	Buy	87,024 +3,829	+5%	+$254K	0.92%	48
2018 Q4	$5.2M	Sell	83,195 -2,143	-3%	-$150K	0.92%	49
2018 Q3	$6.59M	Sell	85,338 -277	-0.3%	-$20.9K	1.03%	46
2018 Q2	$6.07M	Buy	85,615 +3,092	+4%	+$218K	0.97%	52
2018 Q1	$6.22M	Buy	82,523 +646	+0.8%	+$51.4K	1.08%	48
2017 Q4	$5.87M	Buy	81,877 +2,162	+3%	+$164K	0.98%	50
2017 Q3	$6.46M	Buy	79,715 +326	+0.4%	+$24.9K	1.13%	46
2017 Q2	$5.62M	Buy	79,389 +1,754	+2%	+$117K	1%	50
2017 Q1	$5.27M	Buy	+77,635	New	+$5.46M	0.98%	49

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fulton Breakefield Broenniman's GILD Position: Q2 2019 in Review

Fulton Breakefield Broenniman sold out of Gilead Sciences (GILD) in Q2 2019, closing a stake of 87,024 shares — an estimated $5.66M sold.

Fulton Breakefield Broenniman first reported a position in GILD in Q1 2017 and held it in 9 quarters. The position peaked at $6.59M in Q3 2018. 1,483 funds tracked by Wall St. Rank hold GILD as of Q2 2019.

Fulton Breakefield Broenniman reported no remaining Gilead Sciences position as of Q2 2019 after selling out during the quarter.
Fulton Breakefield Broenniman sold 87,024 Gilead Sciences shares in Q2 2019, an estimated $5.66M.
Fulton Breakefield Broenniman first reported a position in Gilead Sciences in Q1 2017 and held it in 9 quarters.
Fulton Breakefield Broenniman's Gilead Sciences position peaked at $6.59M in Q3 2018.
1,483 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2019.

Based on Fulton Breakefield Broenniman's 13F filing for Q2 2019, filed 25 Jul 2019.